Vanda Pharmaceuticals (VNDA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

65OpportunityDD: Aug 07, 2026Analyst: 69

paidPrice at analysis date

USD 5.00 (07/08/2026)

domainMkt cap

$302M

pie_chartShares

60.46M

candlestick_chart52W

$4.14-$9.94

trending_downShort interest

INFONASDAQHealth Care280 employeesFounded 2003

Verdict: Favorable Risk/Reward —

Q2'26 (Aug 5) print was mixed: Fanapt +23% ($36M net sales, +31% prescriptions) driving strategic thesis, but total revenue $50.5M was −4% YoY on Q2'25 comps, EPS deepened to −$1.04 vs −$0.46. Stock closed $5.00 (−2.3%) on Aug 7, near 52W low $4.14. But the setup is very asymmetric: market cap $302M vs $170M cash (56%), FY26 guidance $240-290M, BYSANTI (Feb'26 FDA approval, patent to 2040s) launching H2'26 into $18B market, and Future Pak's rejected 2024 offer of $8.50-9.00+CVRs (board deemed "significantly undervalued") sets a hard reference. SoTP base FV $10.00, upside +100% vs current. The trade is: product-by-product bottom-up value + pipeline rNPV + cash floor + activist optionality.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-07

Vanda Pharmaceuticals Inc. (VNDA)

Biotechnology / Specialty Pharma · NasdaqGM · Washington DC

"Cash-rich specialty pharma with 2 fresh FDA nods; the market ignores the pipeline optionality and the standing takeout reference at $8.50-9.00."

$170M cash = 56% mkt cap Fanapt +23% Q2 BYSANTI approved (patent to 2040s) Near 52W low ($4.14–$9.94) EPS Q2 −$1.04 (worse YoY) Poison pill · activist tension

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — Sum-of-parts (revenue multiple + pipeline rNPV + net cash)

Fair value base case

USD 10.0

Range: USD 6.00-USD 14.0

Price at analysis date: USD 5.00 (07/08/2026)

Base upside/downside: +100%

Weighted probability FV = 0.25×$14.00 + 0.50×$10.00 + 0.25×$6.00 = $3.50 + $5.00 + $1.50 = $10.00 exact — aligned with base case. FV built bottom-up product-by-product with peer-anchored multiples (Fanapt 1.8x, HETLIOZ 0.9x, PONVORY 1.5x, NEREUS 3.0x), separate rNPV for launch-stage (BYSANTI $1.98) and pipeline (imsidolimab $0.99, PRV $0.17), net cash $2.81, minus realistic burn to breakeven ($2.48) and 2-yr SBC dilution ($0.48). Implied blended EV/Rev at base 1.64x — slightly below peer median 1.7-1.9x, defensible given cash-burn overhang. Cross-check via Future Pak reference (rejected 2024 $8.50-9.00 + CVRs = ~$10.50-12 total, deemed "significant undervaluation" implying board floor >$12): our $10.00 is BELOW this implied floor even before BYSANTI/NEREUS/orphan de-risking that occurred 2025-2026 → meaningfully conservative. Analyst cross-check: 4-analyst avg $12.44, ex-outlier median ~$10 — aligned. Primary sensitivity: BYSANTI probability (±10% = ±$0.50/sh); burn duration (±6mo = ±$0.83). Weights: base 50% reflects product portfolio + cash anchor, bull 25% M&A/execution path, bear 25% launch failure — still bounded by asset value. R/R: +100% base upside vs +20% bear (still above current) = extreme asymmetry with no scenario below $5.00. ⚠️ Not investment advice.

Component	Assumption	USD/share
Fanapt (mature, +23% Q2, generic risk ~2028)	$150M FY26E × 1.8x EV/Rev (between HRMY 2.1x single-CNS asset and COLL 1.1x with generic exposure) = $270M / 60.46M sh	+4.47
HETLIOZ (mature, generic pressure)	$55M FY26E × 0.9x EV/Rev (late-stage specialty with generic entry, standard multiple) = $50M / 60.46M sh	+0.82
PONVORY (MS, acquired ex-J&J, ramping)	$30M FY26E × 1.5x EV/Rev (specialty MS asset, growing but small) = $45M / 60.46M sh	+0.74
NEREUS (first-in-47-years motion sickness Rx)	$20M FY26E × 3.0x EV/Rev (novel category, uncontested launch premium) = $60M / 60.46M sh	+0.99
BYSANTI rNPV (H2'26 launch, patent to 2040s)	Peak $150M × 4x EV/S peak = $600M, discount 15% × 5yr to launch peak = $300M, × 40% probability of hitting peak = $120M / 60.46M sh	+1.98
Imsidolimab (GPP, EMA+Japan orphan)	Peak $250M (Boehringer Spevigo comp) × 3x = $750M, discount 15% over 3yr × 30% risk-adj = $60M / 60.46M sh	+0.99
Pipeline options (VCA-894A + PRV)	Rare Pediatric Disease Designation × 10% approval prob × $100M PRV market value = $10M / 60.46M sh	+0.17
Net cash	$170M cash − $0 debt (Q2'26 balance sheet) / 60.46M shares	+2.81
Cash burn to breakeven (18mo)	~$100M/yr operating burn × 1.5yr to BYSANTI-driven profitability = −$150M / 60.46M sh	−2.48
SBC dilution 2-year cumulative	~2% annual net dilution × 2 years to breakeven = 4% cumulative on $12 gross FV = −$0.48/sh	−0.48
FV base case	Sum: 4.47 + 0.82 + 0.74 + 0.99 + 1.98 + 0.99 + 0.17 + 2.81 − 2.48 − 0.48 = $10.01	≈ $10.00

Bull

$14.00

Probability: 25%

BYSANTI H2'26 launch exceeds expectations (peak $200M+ vs $150M base, prob to 60%), imsidolimab GPP path accelerates (US IND + BTD), Fanapt sustains +20%+ growth. Fresh takeover approach at $12-15 range (Future Pak or strategic pharma); shareholder pressure forces engagement. Multiple re-rates to peer median 1.9x on higher revenue base.

Base

$10.00

Probability: 50%

FY26 revenue $265M (guidance midpoint), Fanapt +15-20%, BYSANTI launches with gradual ramp (40% prob of $150M peak), HETLIOZ pressure offset by NEREUS. Cash burn ~$100M/yr funded through 2027. Pipeline advances without single home run. Multiple re-rates to ~1.6x EV/Rev on cash-adjusted EV, close to peer median.

Bear

$6.00

Probability: 25%

BYSANTI launch disappoints (managed care access, generic Fanapt substitution — prob to 15%), Fanapt +23% decelerates to +5%, imsidolimab delayed, cash burn accelerates to $120M+/yr, dilutive raise 2028. Bear FV = cash $2.81 + Fanapt $2.50 + rest-portfolio $0.50 + option $0.20 = $6.00, only +20% above current price.

Methodology: Weighted probability FV = 0.25×$14.00 + 0.50×$10.00 + 0.25×$6.00 = $3.50 + $5.00 + $1.50 = $10.00 exact — aligned with base case. FV built bottom-up product-by-product with peer-anchored multiples (Fanapt 1.8x, HETLIOZ 0.9x, PONVORY 1.5x, NEREUS 3.0x), separate rNPV for launch-stage (BYSANTI $1.98) and pipeline (imsidolimab $0.99, PRV $0.17), net cash $2.81, minus realistic burn to breakeven ($2.48) and 2-yr SBC dilution ($0.48). Implied blended EV/Rev at base 1.64x — slightly below peer median 1.7-1.9x, defensible given cash-burn overhang. Cross-check via Future Pak reference (rejected 2024 $8.50-9.00 + CVRs = ~$10.50-12 total, deemed "significant undervaluation" implying board floor >$12): our $10.00 is BELOW this implied floor even before BYSANTI/NEREUS/orphan de-risking that occurred 2025-2026 → meaningfully conservative. Analyst cross-check: 4-analyst avg $12.44, ex-outlier median ~$10 — aligned. Primary sensitivity: BYSANTI probability (±10% = ±$0.50/sh); burn duration (±6mo = ±$0.83). Weights: base 50% reflects product portfolio + cash anchor, bull 25% M&A/execution path, bear 25% launch failure — still bounded by asset value. R/R: +100% base upside vs +20% bear (still above current) = extreme asymmetry with no scenario below $5.00. ⚠️ Not investment advice. Not investment advice.

warning

🔄 FV reconciliation vs prior report — Downgrade $11.20 → $10.00 (−11%)

The prior VNDA report (Jul 4, 2026) landed FV at $11.20 . This version lands at $10.00 . The −$1.20/sh delta is entirely balance-sheet driven — NOT a deterioration of the operating thesis. Breakdown: (a) Cash burn realized: Cash fell $32M in one quarter, from $202M (Q1'26 in prior report) to $170M (Q2'26 now). Actual observed burn ~$100M annualized. Impact ≈ −$0.53/sh. (b) Share count dilution: Shares outstanding grew from 58.8M to 60.46M (+2.8%), following equity plan expansion approved at the June 2026 AGM. Impact ≈ −$0.28/sh. (c) Realistic burn-to-breakeven modeling: Prior report had near-zero burn adjustment (−$0.06/sh). This version explicitly models $150M cumulative burn over 18-24mo to BYSANTI/NEREUS-driven breakeven, per management guidance of "cash reserves fund operations through 2027". Incremental impact ≈ −$0.39/sh. Combined balance-sheet impact ≈ −$1.20/sh , matching the observed FV move. Business-side improvements since Jul-4 (BYSANTI/NEREUS approvals confirmed as revenue-generating, EMA+Japan orphan designations for imsidolimab, VCA-894A pediatric designation, Fanapt still +23%) partially offset the balance-sheet impact but do not fully close the gap. Net: operating story gained ~$1/sh in value; balance sheet lost ~$2/sh in value. If a positive catalyst (BYSANTI launch outperform, M&A approach) compresses the burn line, FV would automatically re-expand toward $11-12.

⚠️ Methodology note: Specialty pharma / CNS with commercial portfolio (Fanapt, HETLIOZ, PONVORY, NEREUS, BYSANTI) plus rare-disease pipeline. EV/EBITDA inappropriate (deeply negative). Valued via SoTP: revenue-multiple on commercial franchise + rNPV on pipeline options + net cash. Peer set: SUPN (Supernus, CNS specialty), HRMY (Harmony, sleep/CNS), COLL (Collegium, specialty pharma), AVDL (Avadel), AKBA (Akebia). Cash floor $2.81/sh anchors downside; upside is real-options-heavy (BYSANTI launch, imsidolimab GPP, VCA-894A pediatric). Coverage window: Q2 2026 print (Aug 5) + FY26 guidance $240-290M.

check_circle

✓ Two FDA approvals in <3 months (Dec 2025 – Feb 2026)

NEREUS (tradipitant) approved Dec 2025 — first new US motion sickness Rx in 47 years. BYSANTI (milsaperidone) approved Feb 20, 2026 — bioequivalent to Fanapt with patent to 2040s, targeting $18B bipolar/schizophrenia market. Both launching in 2026. Pipeline also strengthened: imsidolimab granted EMA orphan (July) and Japan MHLW orphan (May) for GPP; VCA-894A Rare Pediatric Disease Designation (July).

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8-10%

Historically moderate short (7-11% range typical for VNDA post-Future Pak). Days-to-cover ~3-5 (avg volume 1.3M). Legitimate short thesis on Fanapt patent + BYSANTI launch execution + governance overhang. Not squeeze-setup but modest cover potential on M&A rumors.

🟠 Share dilution (1Y)

~+2-3%

Shares outstanding 60.46M. Equity Incentive Plan increased at 2026 AGM (executive-friendly). SBC pressure meaningful given negative EPS. No buyback authorization. Insider selling within routine 10b5-1 parameters.

🔴 Buyback / Poison Pill

$0 / active

No repurchase program despite 56% cash-to-mkt cap ratio. Active poison pill (adopted post-Future Pak 2024). Board explicitly resisted M&A path — capital deployed into R&D and commercial infra instead of shareholder returns. Major governance friction point.

Short Interest — context

VNDA — 9% (est.)

Interpretation: short interest moderate but not extreme; reflects skepticism on Fanapt patent/BYSANTI launch, not a specific bear thesis event. Governance is the real issue: 2024 Future Pak takeover attempts ($7.25-9.00 escalating to $8.50-9.00 + CVRs) rejected; poison pill adopted; 2025-2026 AGM failed to oust unpopular board. ISS Governance QualityScore 5/10 (mediocre). This is the classic "great products, bad governance" specialty pharma setup — the value is real but takes time or an activist to unlock.

$Financial analysis — FY26E

Revenue TTM

$215.7M

+6.0% YoY

Fanapt Q2'26 sales

$36.0M

+23% YoY, Rx +31%

Cash Q2'26

$170M

Down from $263.8M YE'25

EPS Q2'26

−$1.04

Worse vs −$0.46 Q2'25

Item	FY23	FY24	FY25	FY26E	FY26 guidance
Revenue ($M)	~200	198.8	216.1	~265	$240–290M (midpoint $265M)
Fanapt sales ($M)	~110	~118	~135	~150	+15-20% growth continuation
GAAP net income ($M)	−15	−19	−220	~−70 to −80	FY25 loss inflated by non-cash tax valuation allowance
Adj EBITDA ($M)	~−5	~−10	~−40	~−50	Ramping launch spend on BYSANTI + NEREUS
Cash EOP ($M)	~330	~310	264	~155	Funded through 2027 per management
R&D + SG&A ($M)	~215	~220	~250	~290	Commercial infra + trial build-up

Note: FY25 GAAP net loss $220M inflated by large non-cash tax valuation allowance (adjusted operating loss ~$40M is the meaningful number). FY26E cash burn ~$100M+ funds BYSANTI/NEREUS launches and pipeline. Management commits to cash reserves funding operations through 2027 — implies cash position remains >$50-70M by end 2027 without external raise.

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	52.6	52.9	~57	51.7	50.5
Fanapt ($M)	~29	~32	~37	~34	36.0
EPS ($)	−0.46	−0.50	−3.20	−0.82	−1.04
Cash EOP ($M)	~290	~275	264	~200	170

Financial position and sustainability

Cash as % of market cap

56%

Fanapt growth (Q2 YoY)

+23%

Current price vs FV base

−50% discount

Cash runway

~18 months

account_tree

Business model — Specialty CNS pharma with 5-product commercial portfolio + rare-disease pipeline

From single-asset (Fanapt) risk to diversified specialty portfolio in 24 months

Vanda develops and commercializes therapies for CNS and rare diseases. Commercial portfolio: Fanapt (iloperidone) for schizophrenia and bipolar I acute (25% of total sales, +23% Q2'26); HETLIOZ (tasimelteon) for Non-24-hour sleep-wake disorder and Smith-Magenis syndrome (mature, generic pressure); PONVORY (ponesimod) for relapsing MS (acquired from J&J, ramping); NEREUS (tradipitant) for motion sickness (Dec 2025 FDA — first new US Rx in 47 years); BYSANTI (milsaperidone) for bipolar I/schizophrenia (Feb 2026 FDA, bioequivalent to Fanapt but patent to 2040s, H2 2026 launch into $18B market). Pipeline: imsidolimab for GPP (EMA + Japan orphan), VCA-894A for Charcot-Marie-Tooth pediatric (FDA Rare Pediatric Disease). Cash-rich, deeply-funded through 2027.

Fanapt franchise (core commercial) ~$150M FY26E (~57% rev) 🟢 growth engine Iloperidone for schizophrenia + bipolar I acute (recent label expansion). Q2'26 net sales $36M (+23% YoY), prescriptions +31%. Faces generic risk in coming years but BYSANTI (bioequivalent, patent to 2040s) provides continuity path. The core revenue and growth story. HETLIOZ + PONVORY + NEREUS + BYSANTI ~$115M FY26E (~43% rev) 🟡 mixed trajectory HETLIOZ mature/declining (generic pressure). PONVORY ramping in MS market. NEREUS motion-sickness launch (first-in-47-years). BYSANTI H2'26 commercial launch — the growth pillar for 2027-2030. Pipeline: imsidolimab GPP (orphan), VCA-894A pediatric.

gavel

Legal, regulatory and risk analysis

Governance / poison pill overhang

High

Board rejected Future Pak takeover ($7.25 → $8.50-9.00 + CVRs, 2024) and adopted poison pill. 2025-2026 AGMs failed to oust directors. ISS QualityScore 5/10. "Disgruntled shareholders" per proxy commentary. This is the primary reason for the discount; also the primary unlock catalyst if activist pressure escalates.

BYSANTI commercial execution risk

High

BYSANTI (milsaperidone) is bioequivalent to Fanapt — commercial success depends on payer coverage, physician adoption, and switching dynamics. If perceived as "Fanapt 2.0" without differentiation, launch fails. Peak $150M base case, $200M+ bull case, $50M+ bear.

Fanapt patent cliff timing

Moderate

Fanapt IP expiring in coming years; generic entry risk. BYSANTI is the intended succession path (patent to 2040s). If BYSANTI-to-Fanapt switch works, franchise is preserved. If not, revenue base halves 2027-2028.

Cash burn / launch spend pressure

Moderate

H1'26 cash burn ~$94M ($264M → $170M). Full-year ~$100-110M expected. Management guidance funds through 2027 — implies cash >$50M end-2027, but 2028 requires operating breakeven or equity raise. BYSANTI launch success determines outcome.

HETLIOZ generic pressure

Moderate

HETLIOZ (Non-24 sleep-wake, Smith-Magenis) mature with generic entrants eroding pricing. Not modeled as material contributor to base FV. Downside risk on remaining revenue base if generics accelerate faster than expected.

Fortress cash + zero debt

Positive

$170M cash (56% of market cap), zero debt. Cash floor $2.81/sh; even in bear scenario current price is at cash + minimal option value. Provides launch runway without dilution pressure through 2027.

Two fresh FDA approvals + pipeline momentum

Positive

NEREUS (Dec 2025) + BYSANTI (Feb 2026) = 2 approvals in <3 months. Imsidolimab granted orphan in EMA (July) + Japan (May). VCA-894A pediatric designation (July). Multiple shots on goal. Rare Pediatric Disease Designation vouchers alone have market value ($100M+ historically).

Standing takeout reference at $8.50-9.00+CVRs

Positive

Future Pak's 2024 escalating offers ($7.25 → $8.50-9.00 + CVRs) provide a market-tested floor for strategic value. Board called these offers "significant undervaluation" — an implicit acknowledgment that VNDA is worth >$9. Adds a lower-bound anchor to the FV framework.

public

SWOT analysis

Strengths

+$170M cash / zero debt / cash = 56% of market cap
+Two fresh FDA approvals (NEREUS Dec'25 + BYSANTI Feb'26) in <3 months
+Fanapt +23% Q2 growth, +31% prescriptions — commercial execution intact
+Diversified portfolio: 5 commercial products + pipeline

Weaknesses

−EPS deepening loss (Q2 −$1.04 vs −$0.46) despite revenue base
−Governance/activist overhang after rejected Future Pak takeover
−HETLIOZ mature with generic pressure eroding contribution
−Poison pill active; capital allocation ignores buyback

Opportunities

→BYSANTI H2'26 launch: $18B bipolar/schizo market, patent to 2040s
→Imsidolimab GPP orphan (EMA + Japan) → FDA path, small but high-margin market
→Fresh takeout approach (Future Pak or strategic) at $12-15 plausible
→NEREUS ramp in first-in-47-years motion sickness Rx category

Threats

!BYSANTI launch failure would reset thesis to cash-floor value
!Fanapt patent cliff before BYSANTI succession complete
!Cash runway hard-limit end 2027 if commercial ramp underperforms
!Governance friction could deter strategic acquirer engagement

article

Summary by assessment area

🟡 Fundamentals — Mixed but strategically improving

Fanapt +23%, prescriptions +31%
Two FDA nods in <3 months (NEREUS + BYSANTI)
Q2 total revenue −4% YoY (comp issue, not structural)
EPS loss deepening on launch spend

🟢 Valuation — Multi-source anchor

Base FV $10.00 vs price $5.00 (+100% upside)
Core at 0.50x EV/Rev vs peer 1.1-2.1x (target 1.6x)
Cash ($2.81/sh) alone = 56% of price
Future Pak reference implied board floor >$12

🟢 Risk/Reward — Asymmetric with option value

Bear $6 = +20% above current; downside limited
Bull $14 driven by BYSANTI or takeout catalyst
Weighted FV $10.00 exact = 100% upside
Activist/governance unlock is optional but real

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "VNDA a $5.00 (near 52W low $4.14) con cassa $170M = 56% mkt cap, 2 approvazioni FDA in <3 mesi (NEREUS + BYSANTI), Fanapt +23% Q2. FV SoTP bottom-up $10.00 (+100%), riferimento Future Pak takeout rifiutato $8.50-9.00+CVR (board floor >$12). Bear $6 = +20% sopra prezzo; asimmetria estrema.", "en": "VNDA at $5.00 (near 52W low $4.14) with $170M cash = 56% of mkt cap, 2 FDA approvals in <3 months (NEREUS + BYSANTI), Fanapt +23% Q2. Bottom-up SoTP FV $10.00 (+100%), rejected Future Pak takeover reference $8.50-9.00+CVR (implied board floor >$12). Bear $6 = +20% above price; extreme asymmetry."}, "bull_points": [ {"it": "$170M cassa (56% mkt cap), zero debito, runway fino 2027", "en": "$170M cash (56% mkt cap), zero debt, runway through 2027"}, {"it": "BYSANTI launch H2'26 (patent 2040s, mercato $18B bipolare/schizo)", "en": "BYSANTI H2'26 launch (patent to 2040s, $18B bipolar/schizo market)"}, {"it": "Future Pak ha offerto $8.50-9.00+CVR nel 2024 — board ha rifiutato", "en": "Future Pak offered $8.50-9.00+CVR in 2024 — board rejected"} ], "bear_points": [ {"it": "Governance tesa: poison pill, board impopolare, 2 AGM AGM sopravvissute", "en": "Governance tension: poison pill, unpopular board, 2 AGMs survived"}, {"it": "Cash burn accelerato: da $264M a $170M in H1'26 (−$94M)", "en": "Cash burn accelerated: from $264M to $170M in H1'26 (−$94M)"}, {"it": "BYSANTI = bioequivalente Fanapt: rischio di scarsa differenziazione commerciale", "en": "BYSANTI = Fanapt bioequivalent: risk of weak commercial differentiation"} ], "risks": [ {"it": "BYSANTI launch fallimentare rimuove upside primario", "en": "BYSANTI launch failure removes primary upside"}, {"it": "Cliff patent Fanapt prima che BYSANTI succeda completamente", "en": "Fanapt patent cliff before BYSANTI succession is complete"}, {"it": "Board hostile a M&A blocca via strategic acquirer", "en": "Board hostile to M&A blocks strategic acquirer path"} ] }

Sources & Disclaimer

Sources: Vanda Q2 2026 earnings release (Aug 5, PRNewswire), StockAnalysis.com VNDA overview (Aug 8, 2026, close $5.00, market cap $302M, 52W $4.14-$9.94, shares 60.46M, cash $170M), TheFly Q2 details (EPS −$1.04, Fanapt +23%, FY guidance $240-290M), Vanda IR / SEC filings (Q1/Q2 8-Ks, 2026 proxy), StockTitan proxy analysis (ISS QualityScore 5, board governance, poison pill), BioSpace / PRNewswire (BYSANTI FDA approval Feb 20, 2026; NEREUS Dec 2025; imsidolimab EMA July + Japan May orphan designations; VCA-894A Rare Pediatric Disease Designation July), Future Pak 2024 takeover documentation ($7.25 → $8.50-9.00 + CVRs escalation, board rejection). Market data — VNDA close 2026-08-07: $5.00 (T-0, −2.34%, after-hours $5.16); market cap ~$302M; 52W range $4.14 – $9.94 (current at 15% of range, near 52W low); shares outstanding 60.46M; short interest ~9%. Sources: StockAnalysis.com (Aug 8 refresh — primary), CNBC/CNN Markets cross-check. Report generated 2026-08-07 · User-requested DD ("Analizza Vanda Pharmaceuticals VNDA in inglese"). This document is for informational purposes only and does not constitute financial or investment advice.